Synthetic Oligonucleotides Markets 2027–2031

Synthetic Oligonucleotides Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027–2031

Global forecasts by oligo length, application, product, category and type, for 14 countries and regions, with 34 company profiles.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Synthetic oligonucleotides are becoming a medicines business. Oligonucleotide drugs are reaching large patient populations, large pharma is paying billions for oligo platforms, and contract manufacturers are adding capacity as fast as they can while BIOSECURE pushes drug developers to spread their supply. The market grows from $4,380 million in 2026 to $8,100 million in 2031, at 13.1% a year. Therapeutics overtakes Research as the largest application, and custom, RNA and long oligos gain share.

Market Size 2026: USD $4.38B Market Size 2031: USD $8.1B CAGR: 13.1%

Situation Analysis: what is really happening

• Oligo medicines reach large markets. The FDA approved Ionis's Tryngolza for severe hypertriglyceridemia, and Alnylam's Amvuttra sales rose 106% in the second quarter of 2026.
• Large pharma pays for platforms. Novartis completed its roughly $12 billion purchase of Avidity Biosciences in February 2026.
• CDMOs race to add capacity. WuXi TIDES grew first-half revenue 44.3%, Bachem expects 35% to 40% growth, and Agilent and ST Pharm are adding plants.
• BIOSECURE is now law. The Act was enacted in December 2025, and Western drug developers are spreading their supply across more manufacturers.
• Long DNA and new synthesis methods advance. Twist reported record revenue, Ansa is scaling enzymatic synthesis of long DNA, and DNA data storage is the fastest growing application.
• RNA gains ground. RNA oligos grow 17.5% a year, from 16.5% to 20.0% of the market, as primers lose share.

Company Analysis: who is positioned, who is exposed

• IDT (Danaher), Thermo Fisher, Merck KGaA and Eurofins Genomics: Lead research and diagnostic oligo supply.
• WuXi TIDES, Agilent, Bachem, Nitto Avecia and ST Pharm: Contract manufacturers adding drug-substance capacity.
• Alnylam, Ionis, Arrowhead and Novartis: Drug developers whose launches drive demand for GMP oligos.
• Hongene, ChemGenes and LGC Biosearch: Supply the nucleosides and phosphoramidites the industry depends on.
• Twist, Ansa, DNA Script and Atlas Data Storage: Push long DNA, enzymatic synthesis and data storage.

In all, 34 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Questions this report answers

• How fast will oligonucleotide therapeutics grow, and when do they overtake research?
• Which CDMOs are adding capacity, and how will BIOSECURE change where drug substance is made?
• How fast are RNA, custom and long oligos gaining share?
• Will enzymatic synthesis replace phosphoramidite chemistry, and when?
• How large could DNA data storage become?
• How large is each country market, and how fast is China growing?

What's inside

• 260 pages, 23 chapters, 58 tables and 46 figures
• Forecasts for 2027–2031 from a 2026 base year, by oligo length, application, product, category and type, for 14 countries and regions
• Research and diagnostic oligos, oligonucleotide therapeutics and CDMO manufacturing, and gene synthesis and long DNA
• Raw materials, instruments, automation and DNA data storage, regulation, biosecurity and policy, and China and Asia-Pacific
• 10 market-moving developments from 2025 and 2026, SWOT, Porter's Five Forces and strategic recommendations
• 34 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Oligo suppliers and CDMOs: plan capacity, pricing and customers for a market led by medicines.
• Raw material and instrument companies: size demand for phosphoramidites, reagents and synthesizers.
• Investors and analysts: assess growth, capacity build-out and BIOSECURE exposure.
• Drug developers and procurement teams: plan drug-substance supply and diversify manufacturers.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.